Leerink cautious on Intercept ahead of FLINT data Leerink initiated shares of Intercept with a Market Perform rating saying it is cautious ahead of the full FLINT data. The firmís talks with a specialist indicated that robust improvements in fibrosis are required to offset concerns about plasma lipids and excess cardiovascular events. Leerink set a $270 price target for the stock. Shares of Intercept were also initiated this morning at Nomura with a Neutral rating.
Intercept gets breakthrough designation from FDA for steatohepatitis treatment Intercept Pharmaceuticals announced that its investigational product obeticholic acid, or OCA, has received "breakthrough therapy designation" from the FDA for the treatment of patients with nonalcoholic steatohepatitis, or NASH, with liver fibrosis. This indication constitutes a population of patients with a serious and life-threatening condition reflected by a higher risk of progression to cirrhosis and liver failure. OCA is currently being developed for the treatment of several chronic liver diseases, including primary biliary cirrhosis, NASH and primary sclerosing cholangitis.